Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 22762459)

1.

Interleukin-28B polymorphisms are associated with fibrosing cholestatic hepatitis in recurrent hepatitis C after liver transplantation.

Hanouneh IA, Zein NN, Askar M, Lopez R, John B.

Clin Transplant. 2012 Jul-Aug;26(4):E335-6. doi: 10.1111/j.1399-0012.2012.01678.x. Epub 2012 Jul 4. No abstract available.

PMID:
22762459
2.

Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation.

Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, Hassoba H, Wright TL.

Hepatology. 1999 Dec;30(6):1513-20.

PMID:
10573532
3.

Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.

Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S.

Transplant Proc. 2011 Apr;43(3):905-8. doi: 10.1016/j.transproceed.2011.02.034.

PMID:
21486625
4.

Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.

Delladetsima JK, Boletis JN, Makris F, Psichogiou M, Kostakis A, Hatzakis A.

Liver Transpl Surg. 1999 Jul;5(4):294-300.

PMID:
10388502
5.

Association of polymorphisms in interleukin-18 and interleukin-28B with hepatitis B recurrence after liver transplantation in Chinese Han population.

Li Y, Shi Y, Chen J, Cai B, Ying B, Wang L.

Int J Immunogenet. 2012 Aug;39(4):346-52. doi: 10.1111/j.1744-313X.2012.01097.x. Epub 2012 Feb 10.

PMID:
22325058
6.

Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy.

Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, Neuhaus P, Neumann U, Seehofer D.

Transplantation. 2012 Mar 27;93(6):644-9. doi: 10.1097/TP.0b013e318244f774.

PMID:
22411462
7.

Early, rapidly progressive cholestatic hepatitis C reinfection and graft loss after adult living donor liver transplantation.

Troppmann C, Rossaro L, Perez RV, McVicar JP.

Am J Transplant. 2003 Feb;3(2):239-40. No abstract available.

8.

[Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation].

Kim BK, Kwon SY, Ko SY, Choe WH, Lee CH, Han HS, Chang SH.

Korean J Hepatol. 2008 Dec;14(4):519-24. doi: 10.3350/kjhep.2008.14.4.519. Korean.

9.

Impact of IL-28B polymorphism on outcome in patients with hepatitis C after liver transplantation.

Neumann U.

Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):429-31. doi: 10.1586/egh.11.54. No abstract available.

PMID:
21780887
10.

Post-transplant recurrent hepatitis C: immunohistochemical detection of hepatitis C virus core antigen and possible pathogenic implications.

Pessôa MG, Alves VA, Wakamatsu A, Gomes JG, Maertens G, van der Borght B, Kim M, Ferrell L, Wright TL.

Liver Int. 2008 Jul;28(6):807-13. doi: 10.1111/j.1478-3231.2008.01739.x.

PMID:
18422936
11.

Intrahepatic cholestasis following liver transplantation.

Te HS, Baker AL.

Clin Liver Dis. 1999 Aug;3(3):633-49, x. Review.

PMID:
11291242
12.

Liver transplantation and hepatitis C: will understanding the interleukin-28B polymorphisms improve outcomes?

McCaughan GW, Shackel NA, Bowen DG.

Liver Transpl. 2011 Mar;17(3):219-21. doi: 10.1002/lt.22252. No abstract available.

13.

Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used.

Bitetto D, Fabris C, Falleti E, Fornasiere E, Avellini C, Cmet S, Cussigh A, Fontanini E, Pirisi M, Corradini SG, Merli M, Molinaro A, Toniutto P.

Transplantation. 2012 May 27;93(10):1038-44. doi: 10.1097/TP.0b013e31824df7f3.

PMID:
22495472
14.

Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation.

Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, Zhang D, Gerber MA, Miller CM, Bodenheimer HC Jr.

Hepatology. 1996 May;23(5):971-6.

PMID:
8621177
15.
16.

[Acute hepatitis C infection with prolonged intrahepatic cholestasis and remarkable progression of fibrosis mimicking fibrosing cholestatic hepatitis].

Akagi H, Mizuki A, Tominaga T, Seki Y, Nakajima R, Matsumoto Y, Nakashita M, Okazawa A, Sato T, Nagata H.

Nihon Shokakibyo Gakkai Zasshi. 2014 Jun;111(6):1141-8. Japanese.

PMID:
24898494
17.

Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy.

Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, Cosimi AB.

Transplantation. 1998 Nov 15;66(9):1254-8.

PMID:
9825826
18.

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.

Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M.

Liver Transpl. 2011 Mar;17(3):289-98. doi: 10.1002/lt.22235.

19.

Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy.

Bolkhir A, Brunt EM, Solomon HS, Hayashi PH.

Liver Transpl. 2007 Feb;13(2):309-11; author reply 312. No abstract available.

20.

Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860.

Cisneros E, Baños I, Citores MJ, Duca A, Salas C, Noblejas A, Cañizares M, Millán I, Cuervas-Mons V, Vilches C.

Transplantation. 2012 Aug 15;94(3):275-80.

PMID:
22790387
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk